Adjusted Body Weight (ABW) Calculator

Dosing weight: ABW with correction factor 0.4.

Aminoglycosides are hydrophilic drugs that distribute primarily into extracellular fluid. In obese patients, the volume of distribution increases — but not proportionally with total body weight, because adipose tissue has relatively low water content. The seminal study by Bauer et al. (1983) demonstrated that using a 0.4 correction factor provided drug levels closest to those predicted by measured pharmacokinetic parameters.

• Gentamicin/Tobramycin: Dose at 5–7 mg/kg ABW for extended-interval dosing. Traditional dosing: 1.5–2.5 mg/kg ABW q8h.
• Amikacin: Dose at 15–20 mg/kg ABW for extended-interval dosing.
• Monitoring: Therapeutic drug monitoring is essential in obese patients regardless of the weight used. Target peak and trough levels according to institutional guidelines.

In morbidly obese patients (> 200% IBW), the 0.4 correction factor may underestimate the true volume of distribution. Some pharmacokinetic models suggest a CF of 0.43–0.58 may be more appropriate at extreme weights — consult clinical pharmacist.

Dosing weight: Actual body weight — not ABW.

Vancomycin has a volume of distribution that correlates with total body weight, including adipose tissue. Current ASHP/IDSA/SIDP guidelines (2020 revision) recommend using actual body weight for initial dosing, with a target AUC/MIC of 400–600 for serious MRSA infections.

• Loading dose: 25–30 mg/kg actual weight (max single dose varies by institution, often 3,000 mg).
• Maintenance: 15–20 mg/kg actual weight q8–12h, guided by AUC-based monitoring.
• Monitoring: AUC-guided dosing is now preferred over trough-only monitoring. In obese patients, creatinine clearance is often overestimated — requiring dose adjustment.

Using ABW or IBW for vancomycin in obese patients leads to subtherapeutic levels and treatment failure. This is a common and clinically important error.

Dosing weight: Actual body weight for therapeutic doses — not ABW.

Enoxaparin distributes into plasma and extracellular fluid in proportion to total body weight. For therapeutic anticoagulation, the standard dose is 1 mg/kg actual weight subcutaneously every 12 hours. Studies in obese patients (up to 144 kg) have shown predictable anti-Xa levels when dosed on actual weight.

• Therapeutic dosing: 1 mg/kg actual weight q12h. Anti-Xa monitoring is recommended at weights > 150 kg.
• Prophylactic dosing: Weight-based prophylaxis (e.g., 40 mg q12h) is often used in bariatric patients, though optimal dosing remains debated.
• Dose capping: Some institutions cap therapeutic doses at 150 kg actual weight and monitor anti-Xa levels above this threshold.

Dosing weight: Generally standard fixed doses; if weight-based, consider ABW with CF 0.3.

Most fluoroquinolones are dosed as fixed doses (e.g., ciprofloxacin 400 mg IV, levofloxacin 750 mg PO) that do not require weight-based calculations in standard practice. However, in pharmacokinetic models and some institutional guidelines, a correction factor of approximately 0.3 has been suggested when weight-based adjustments are necessary.

Fluoroquinolones have moderate tissue penetration including into adipose tissue, but the volume of distribution does not increase linearly with total body mass. In morbidly obese patients, standard fixed doses may produce lower-than-expected serum concentrations, though clinical outcomes data are limited.

Neuromuscular blockers illustrate why no single weight scalar fits all drugs, even within one pharmacological class.

• Succinylcholine: Dose on actual body weight. Pseudocholinesterase activity increases with body mass, so higher doses are needed to achieve neuromuscular blockade in obese patients.
• Rocuronium / Vecuronium / Cisatracurium: Dose on IBW. These non-depolarising agents distribute into lean tissue and have a limited volume of distribution in adipose tissue. Using actual weight leads to prolonged paralysis — a significant safety concern in the obese surgical patient.

ABW is generally not used for neuromuscular blockers. The clinical decision is between IBW (non-depolarising) and actual weight (succinylcholine).

Anaesthetic dosing in obesity is particularly nuanced because different drugs have dramatically different fat solubilities and distribution characteristics.

• Propofol (induction): Loading dose on lean body weight (LBW) — not ABW or actual weight. Maintenance infusion is based on actual weight due to high lipophilicity and redistribution.
• Thiopental: Dose on lean body weight. Highly lipophilic but initial distribution is into lean tissue.
• Fentanyl / Sufentanil: Loading dose on lean body weight to avoid respiratory depression. Infusion rates may use actual weight for highly lipophilic drugs with redistribution.
• Remifentanil: Dose on IBW. Minimal redistribution into fat; actual weight dosing causes significant respiratory depression.

Note that anaesthetic dosing often uses lean body weight (Janmahasatian formula) rather than ABW. These are distinct concepts — LBW accounts for total lean mass, while ABW is a simplified correction above IBW.

The most frequent error is applying ABW universally to every weight-based drug dose in an obese patient. ABW is pharmacokinetically appropriate only for drugs whose volume of distribution partially — but not fully — extends into adipose tissue (primarily hydrophilic drugs with moderate tissue penetration).

Using ABW for vancomycin leads to subtherapeutic levels and potential treatment failure, because vancomycin’s volume of distribution scales with total body mass. Conversely, using ABW for non-depolarising neuromuscular blockers (which should use IBW) would lead to overdosing and prolonged paralysis. Always consult drug-specific guidelines — ABW is not a universal scalar.

When actual weight is less than IBW, the ABW formula yields a value below actual weight: ABW = IBW + 0.4 × (negative number). This is mathematically valid but clinically meaningless. The ABW concept assumes excess adipose tissue — it has no pharmacokinetic rationale in underweight patients.

For patients weighing less than IBW, dose using actual body weight and adjust for the underlying clinical condition (e.g., reduced renal function in cachexia, altered protein binding in malnutrition). The ABW calculator should explicitly flag when actual weight ≤ IBW and recommend actual weight dosing instead.

The 0.4 correction factor is specific to aminoglycoside pharmacokinetics and was derived from a relatively small study population. It has been adopted as a convenient default, but it does not reflect the pharmacokinetics of all drug classes. Some β-lactams may have a higher correction factor (~0.45), while some fluoroquinolones may warrant a lower factor (~0.3).

In clinical practice, the 0.4 factor is reasonable as a starting point for hydrophilic drugs when drug-specific data are unavailable. However, clinicians should not assume precision — ABW is an estimate, and therapeutic drug monitoring provides a far more reliable guide to dosing adequacy than any weight-based formula.

ABW and lean body weight (LBW) are distinct pharmacokinetic concepts that are frequently confused.

ABW = IBW + CF × (Actual − IBW). It is a simplified linear adjustment above IBW designed for drug dosing. It uses the Devine IBW formula and a fixed correction factor.

LBW is an estimate of fat-free mass, typically calculated using the Janmahasatian formula: LBW = 9,270 × weight / (6,680 + 216 × BMI) for males, or 9,270 × weight / (8,780 + 244 × BMI) for females. LBW accounts for both height and weight and provides a non-linear, physiologically-based estimate of lean tissue mass.

Anaesthetic dosing (propofol, fentanyl) typically uses LBW, not ABW. Aminoglycoside dosing uses ABW, not LBW. Using the wrong metric in either context can lead to clinically significant dosing errors.

ABW adjusts the dose for the volume of distribution in obesity — it does not account for drug clearance. Many weight-dosed drugs (aminoglycosides, vancomycin) are renally cleared, and obese patients frequently have altered renal function. An obese patient may need ABW-based dosing and a separate renal dose adjustment.

Furthermore, estimating creatinine clearance in obese patients is itself problematic — the Cockcroft-Gault equation uses body weight, and whether to use actual weight, IBW, or ABW in the equation remains debated. Many institutions use actual weight in Cockcroft-Gault but cap at a maximum (e.g., no higher than the value at 120% IBW). Always adjust dosing intervals and amounts based on renal function independently of the ABW calculation.